The dopamine transporter: Role in neurotoxicity and human disease

Toxicology and Applied Pharmacology

Volumn 204, Issue 3, 2005, Pages 355-360

  Bannon, Michael J ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine transporter; Human disease; Neurotoxicity

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALPHA SYNUCLEIN; AMPHETAMINE; COCAINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; PSYCHOSTIMULANT AGENT; PYRIDINIUM DERIVATIVE;

ATTENTION DEFICIT DISORDER; BIOACCUMULATION; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CORRELATION ANALYSIS; DRUG ABUSE; EXTRACELLULAR SPACE; HUMAN; MENTAL DISEASE; MESENCEPHALON; MISSENSE MUTATION; NERVE CELL; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; REVIEW;

EID: 17444395169     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2004.08.013     Document Type: Review

References (64)

1. M.J. Bannon Dopamine Nature Encyclopedia of Life Sciences 2004 Nature Publishing Group London http://www.els.net
2. M.J. Bannon, and C.J. Whitty Age-related and regional differences in dopamine transporter mRNA expression in human midbrain Neurology 1997 969 977
3. M.J. Bannon, P. Sacchetti, and J.G. Granneman The dopamine transporter: potential involvement in neuropsychiatric disorders S.J. Watson Psychopharmacology: The Fourth Generation of Progress 2000 The American College of Neuropsychopharmacology http://www.acnp.org/g4/4thgen/php
4. M.J. Bannon, S.K. Michelhaugh, J. Wang, and P. Sacchetti The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders Eur. Neuropsychopharmacol. 11 2001 449 455
5. M.J. Bannon, B. Pruetz, A.B. Manning-Bog, C.J. Whitty, S.K. Michelhaugh, P. Sacchetti, J.G. Granneman, D.C. Mash, and C.J. Schmidt Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers Proc. Natl. Acad. Sci. U.S.A. 99 2002 6382 6385
6. M.J. Bannon, B. Pruetz, E. Barfield, and C.J. Schmidt Transcription factors specifying dopamine phenotype are decreased in cocaine users NeuroReport 15 2004 401 404
7. A.M. Carneiro, S.L. Ingram, J.M. Beaulieu, A. Sweeney, S.G. Amara, S.M. Thomas, M.G. Caron, and G.E. Torres The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter J. Neurosci. 22 2002 7045 7054
8. L. Chen, D.M. Segal, C.T. Moraes, and D.C. Mash Dopamine transporter mRNA in autopsy studies of chronic cocaine abusers Mol. Brain Res. 73 1999 181 185
9. 123I]IPT SPECT in children with attention deficit hyperactivity disorder Eur. J. Nucl. Med. Mol. Imaging 30 2003 306 311
10. S. DiMaio, N. Grizenko, and R. Joober Dopamine genes and attention-deficit hyperactivity disorder: a review J. Psychiatry Neurosci. 28 2002 27 38
11. D.M. Donovan, L.L. Miner, M.P. Perry, R.S. Revay, L.G. Sharpe, S. Predborski, V. Kostic, R.M. Philpot, C.L. Kirstein, R.B. Rothman, C.W. Schindler, and G.R. Uhl Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression Mol. Brain Res. 10 1999 37 49
12. D.D. Dougherty, A.A. Bonab, T.J. Spencer, S.L. Rauch, B.K. Madras, and A.J. Fischman Dopamine transporter density in patients with attention deficit hyperactivity disorder Lancet 354 1999 2132 2133
13. 99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment Eur. J. Nucl. Med. 27 2000 1518 1524
14. J.L. Eriksen, T.M. Dawson, D.W. Dicjson, and L. Petrucelli Caught in the act: α-synuclein is the culprit in Parkinson's disease Neuron 40 2003 453 456
15. R.R. Gainetdinov, F. Fumagalli, S.R. Jones, and M.G. Caron Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter J. Neurochem. 69 1997 1322 1325
16. C. Granas, J. Ferrer, C.J. Loland, J.A. Javitch, and U. Gether N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization J. Biol. Chem. 278 2003 4990 5000
17. T.A. Greenwood, and J.R. Kelsoe Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene Genomics 82 2003 511 519
18. K.A. Harrington, S.J. Augood, A.E. Kingsbury, O.J. Foster, and P.C. Emson Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease Mol. Brain Res. 36 1996 157 162
19. Y.L. Hurd, and M. Herkenham Molecular alterations in the neostriatum of human cocaine addicts Synapse 13 1993 357 369
20. L.L. Iversen Role of neurotransmitter uptake mechanisms in synaptic neurotransmission Br. J. Pharmacol. 41 1971 571 591
21. J.N. Joyce, G. Smutzer, C.J. Whitty, A. Myers, and M.J. Bannon Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease Mov. Disord. 12 1997 885 897
22. K.M. Kahlig, and A. Galli Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine Eur. J. Pharmacol. 479 2003 153 158
23. S.J. Kish What is the evidence that ecstasy (MDMA) can cause Parkinson's disease? Mov. Disord. 18 2003 1219 1223
24. K.-H. Krause, S.H. Dresesl, J. Krause, H.F. Kung, and K. Tatsch Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography Neurosci. Lett. 285 2000 107 110
25. K.-H. Krause, S.H. Dresesl, J. Krause, C. la Fougere, and M. Ackenheil The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder Neurosci. Biobehav. Rev. 27 2003 605 613
26. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
27. F.J. Lee, F. Liu, Z.B. Pristupa, and H.B. Niznik Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis FASEB J. 15 2001 916 926
28. Z. Lin, P.W. Zhang, X. Zhu, J.M. Melgari, R. Huff, R.L. Spieldoch, and G.R. Uhl Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporter (DAT) require N-terminal DAT phosphoacceptor sites J. Biol. Chem. 278 2003 20162 20170
29. 3H]WIN 35428 binding sites in human striatum Brain Res. 628 1993 17 25
30. K.Y. Little, D.P. McLaughlin, L. Zhang, P.R. McFinton, G.W. Dalack, E.H. Cook, B.J. Cassin, and S.J. Watson Brain dopamine transporter messenger RNA and binding sites in cocaine users Arch. Gen. Psychiatry 55 1998 793 799
31. B.K. Madras, G.M. Miller, and A.J. Fischman The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD) Behav. Brain Res. 130 2003 57 63
32. 123I]beta-CIT SPECT Am. J. Psychiatry 155 1998 832 834
33. E. Maries, B. Dass, T.J. Collier, J.H. Kordower, and K. Steece-Collier The role of α-synuclein in Parkinson's disease: insights from animal models Nat. Rev., Neurosci. 4 2003 727 738
34. V. Marshall, and D. Grosset Role of dopamine transporter imaging in routine clinical practice Mov. Disord. 12 2003 1415 1423
35. D.C. Mash, J. Pablo, Q. Ouyang, W.L. Hearn, and S. Izenwasser Dopamine transport function is elevated in cocaine users J. Neurochem. 81 2002 292 300
36. 11C]WIN-35,428 J. Neurosci. 18 1998 8417 8422
37. G.W. Miller, M.L. Kirby, A.I. Levey, and J.R. Bloomquist Heptachlor alters expression and function of dopamine transporters Neurotoxicology 20 1999 631 637
38. O.V. Mortensen, and S.G. Amara Dynamic regulation of the dopamine transporter Eur. J. Pharmacol. 479 2003 159 170
39. M.J. Nirenberg, R.A. Vaughan, G.R. Uhl, M.J. Kuhar, and V.M. Pickel The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons J. Neurosci. 16 1996 436 447
40. M.J. Nirenberg, J. Chan, A. Pohorille, R.A. Vaughan, G.R. Uhl, M.J. Kuhar, and V.M. Pickel The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens J. Neurosci. 17 1997 6899 6907
41. Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression JAMA 287 2002 1653 1661
42. 123I]β-CIT SPECT study-preliminary report Psychopharmacology 159 2002 335 340
43. M.K. Sanghera, K.F. Manaye, C.L. Liang, A.M. Iacopino, M.J. Bannon, and D.C. German Low dopamine transporter mRNA levels in midbrain regions containing calbindin NeuroReport 5 1994 1641 1644
44. Y. Sekine, M. Iyo, Y. Ouchi, T. Matsunaga, H. Tsukada, H. Okada, E. Yoshikawa, M. Futatsubashi, N. Takei, and N. Mori Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET Am. J. Psychiatry 158 2001 1206 1214
45. Y. Sekine, Y. Minabe, Y. Ouchi, N. Takei, M. Iyo, K. Nakamura, K. Suzuki, H. Tsukada, H. Okada, E. Yoshikawa, M. Futatsubashi, and N. Mori Association of dopamine transporter loss in the orbital frontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms Am. J. Psychiatry 160 2003 1699 1701
46. A. Sidhu, C. Wersinger, and P. Vernier α-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease FEBS Lett. 565 2004 1 5
47. H.H. Sitte, H. Farhan, and J.A. Javitch Sodium-dependent neurotransmitter transporters: oligomerization as a determinant of transport function and trafficking Mol. Interv. 4 2004 38 46
48. J.K. Staley, W.L. Hearn, A.J. Ruttenber, C.V. Wetli, and D.C. Mash High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims J. Pharmacol. Exp. Ther. 271 1994 1678 1685
49. 123I]beta-CIT SPECT J. Neurol. 245 1998 14 20
50. G.E. Torres, W.D. Yao, A.R. Mohn, H. Quan, K.M. Kim, A.I. Levey, J. Staudinger, and M.G. Caron Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1 Neuron 30 2001 121 134
51. G.R. Uhl Hypothesis: the role of dopamine transporters in selective vulnerability of cells on Parkinson's disease Ann. Neurol. 43 1998 555 560
52. G.R. Uhl Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism Mov. Disord. 18 Suppl. 7 2003 S71 S80
53. G.R. Uhl, D. Walter, D. Mash, B. Faucheux, and F. Javoy-Agid Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons Ann. Neurol. 35 1994 494 498
54. C.H. Van Dyck, D.M. Quinlan, L.M. Cretella, J.K. Staley, R.T. Malison, R.M. Baldwin, J.P. Seibyl, and R.B. Innis Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder Am. J. Psychiatry 159 2002 309 312
55. J.S. Vles, F.J. Feron, J.G. Hendriksen, J. Jolles, M.J. van Krooenburgh, and W.E. Weber Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD) Neuropediatrics 34 2003 77 80
56. N.D. Volkow, L. Chang, G.-J. Wang, J.S. Fowler, D. Franceschi, M. Sedler, S.J. Gatley, E. Miller, R. Hitzemann, Y.-S. Ding, and J. Logan Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence J. Neurosci. 21 2001 9414 9418
57. N.D. Volkow, L. Chang, G.-J. Wang, J.S. Fowler, M. Leonido-Yee, D. Franceschi, M.J. Sedler, S.J. Gatley, R. Hitzemann, Y.-S. Ding, J. Logan, C. Wong, and E.N. Miller Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers Am. J. Psychiatry 158 2001 377 382
58. N.D. Volkow, J.S. Fowler, G.-J. Wang, Y.-S. Ding, and S.J. Gatley Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies Eur. Neuropsychopharmacol. 12 2002 557 566
59. G.-J. Wang, N.D. Volkow, J.S. Fowler, M. Fischman, R. Foltin, N.N. Abumrad, J. Logan, and N.R. Pappas Cocaine abusers do not show loss of dopamine transporters with age Life Sci. 61 1997 1059 1065
60. C. Wersinger, and A. Sidhu Attenuation of dopamine transporter activity by α-synuclein Neurosci. Lett. 340 2003 189 192
61. C. Wersinger, D. Prou, P. Vernier, and A. Sidhu Modulation of dopamine transporter function by α-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress FASEB J. 17 2003 2151 2153
62. J.M. Wilson, K.S. Kalasinsky, A.I. Levey, C. Bergeron, G. Reiber, R.M. Anthony, G.A. Schmunk, K. Shannak, J.W. Haycock, and S.J. Kish Striatal dopamine nerve terminals in human, chronic methamphetamine users Nat. Med. 2 1996 699 703
63. J.M. Wilson, A.I. Levey, C. Bergeron, K. Kalasinsky, L. Ang, F. Peretti, V.I. Adams, J. Smialek, W.R. Anderson, K. Shannak, J. Deck, H.B. Niznik, and S.J. Kish Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users Ann. Neurol. 40 1996 428 439
64. D.F. Wong, J.C. Harris, S. Naidu, F. Yokoi, S. Marenco, R.F. Dannals, H.T. Ravert, M. Yaster, A. Evans, O. Rousset, R.N. Bryan, A. Gjedde, M.J. Kuhar, and G.R. Breese Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo Proc. Natl. Acad. Sci. U.S.A. 28 1996 5539 5543